The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine
Abstract
PURPOSE: To assess thiopurine S-methyltransferase (TPMT) phenotype and genotype in patients who were intolerant to treatment with mercaptopurine (MP) or azathioprine (AZA), and to evaluate their clinical management. PATIENTS AND METHODS: TPMT phenotype and thiopurine metabolism were assessed in all patients referred between 1994 and 1999 for evaluation of excessive toxicity while receiving MP or AZA. TPMT activity was measured by radiochemical analysis, TPMT genotype was determined by mutation-specific polymerase chain reaction restriction fragment length polymorphism analyses for the TPMT*2, *3A, *3B, and *3C alleles, and thiopurine metabolites were measured by high-performance liquid chromatography. RESULTS: Of 23 patients evaluated, six had TPMT deficiency (activity < 5 U/mL of packed RBCs [pRBCs]; homozygous mutant), nine had intermediate TPMT activity (5 to 13 U/mL of pRBCs; heterozygotes), and eight had high TPMT activity (> 13.5 U/mL of pRBCs; homozygous wildtype). The 65.2% frequency of TPMT-deficient and heterozygous individuals among these toxic patients is significantly greater than the expected 10% frequency in the general population (P < .001, χ 2). TPMT phenotype and genotype were concordant in all TPMT-deficient and all homozygous-wildtype patients, whereas five patients with heterozygous phenotypes did not have a TPMT mutation detected. Before thiopurine dosage adjustments, TPMT-deficient patients experienced more frequent hospitalization, more platelet transfusions, and more missed doses of chemotherapy. Hematologic toxicity occurred in more than 90% of patients, whereas hepatotoxicity occurred in six patients (26%). Both patients who presented with only hepatic toxicity had a homozygous-wildtype TPMT phenotype. After adjustment of thiopurine dosages, the TPMT-deficient and heterozygous patients tolerated therapy without acute toxicity. CONCLUSION: There is a significant (> six-fold) overrepresentation of TPMT deficiency or heterozygosity among patients developing dose-limiting hematopoietic toxicity from therapy containing thiopurines. However, with appropriate dosage adjustments, TPMT-deficient and heterozygous patients can be treated with thiopurines, without acute dose-limiting toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Self-citationWeinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Yates, C. R., Krynetski, E. Y., Loennechen, T., Fessing, M. Y., Tai, H.-L., Pui, C.-H., Relling, M. V., & Evans, W. E. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-8-199704150-00003 · Cited by 756
Self-citationRelling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C.-H., & Evans, W. E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2001 · Cited by 733
Self-citationGenetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91745-v · Cited by 651
Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia
Evans, W. E., Relling, M. V., Rodman, J. H., Crom, W. R., Boyett, J. M., & Pui, C.-H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380803 · Cited by 492
Self-citationMcLeod, H., Krynetski, E., Relling, M., & Evans, W. (2000) · Leukemia · doi:10.1038/sj.leu.2401723 · Cited by 437
Self-citationHigh incidence of secondary brain tumours after radiotherapy and antimetabolites
Relling, M. V., Rubnitz, J. E., Rivera, G. K., Boyett, J. M., Hancock, M. L., Felix, C. A., Kun, L. E., Walter, A. W., Evans, W. E., & Pui, C.-H. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11079-6 · Cited by 411
Self-citationPrognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia
Relling, M. V., Hancock, M. L., Boyett, J. M., Pui, C.-H., & Evans, W. E. (1999) · Blood · doi:10.1182/blood.v93.9.2817 · Cited by 395
Self-citationEvans, W. E., Horner, M., Chu, Y. Q., Kalwinsky, D., & Roberts, W. M. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83063-x · Cited by 392
Self-citationHuman thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*
Otterness, D., Szumlanski, C., Lennard, L., Klemetsdal, B., Aarbakke, J., Park-Hah, J. O., Iven, H., Schmiegelow, K., Branum, E., O'Brien, J., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90152-1 · Cited by 390
Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine
Black, A. J., McLeod, H. L., Capell, H. A., Powrie, R. H., Matowe, L. K., Pritchard, S. C., Collie-Duguid, E. S. R., & Reid, D. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-9-199811010-00007 · Cited by 374
Collie-Duguid, E. S. R., Pritchard, Powrie, Sludden, J., Collier, Li, T., & McLeod, H. L. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00006 · Cited by 368
Lennard, L., Van Loon, J. A., Lilleyman, J. S., & Weinshilboum, R. M. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.4 · Cited by 344
Krynetski, E. Y., Schuetz, J. D., Galpin, A. J., Pui, C. H., Relling, M. V., & Evans, W. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.949 · Cited by 306
Self-citationPolymorphism of the thiopurine S-methyltransferase gene in African- Americans
Hon, Y. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.371 · Cited by 271
Self-citationTai, H.-L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y., & Evans, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6444 · Cited by 259
Self-citationThiopurine methyltransferase alleles in British and Ghanaian populations
Ameyaw, M. M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.367 · Cited by 240
Schütz, E., Gummert, J., Mohr, F., & Oellerich, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)93028-y · Cited by 222
McLeod, H., Relling, M., Liu, Q., Pui, C., & Evans, W. (1995) · Blood · doi:10.1182/blood.v85.7.1897.bloodjournal8571897 · Cited by 218
Self-citationEtoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
Relling, M., Yanishevski, Y., Nemec, J., Evans, W., Boyett, J., Behm, F., & Pui, C.-H. (1998) · Leukemia · doi:10.1038/sj.leu.2400928 · Cited by 188
Self-citationPossible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells
Thomsen, J. B., Schr�der, H., Kristinsson, J., Madsen, B., Szumlanski, C. L., Weinshilboum, R. M., Andersen, J. B., & Schmiegelow, K. (1999) · Cancer · Cited by 172
Spire‐Vayron de la Moureyre, C., Debuysere, H., Mastain, B., Vinner, E., Marez, D., Lo Guidice, J., Chevalier, D., Brique, S., Motte, K., Colombel, J., et al. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702152 · Cited by 170
Pharmacogenetics of Cancer Therapy: Getting Personal
Krynetski, E. Y., & Evans, W. E. (1998) · The American Journal of Human Genetics · doi:10.1086/301941 · Cited by 144
Self-citationTai, H.-L., Fessing, M. Y., Bonten, E. J., Yanishevsky, Y., d’Azzo, A., Krynetski, E. Y., & Evans, W. E. (1999) · Pharmacogenetics and Genomics · doi:10.1097/01213011-199910000-00011 · Cited by 132
Self-citationKrynetski, E. Y., Krynetskaia, N. F., Yanishevski, Y., & Evans, W. E. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08754-1 · Cited by 117
Self-citationBodey, G. P., Brodovsky, H. S., Isassi, A. A., Samuels, M. L., & Freireich, E. J. (1968) · PubMed · Cited by 13
Cited by
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Self-citationPui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,277
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Pui, C.-H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A., Baruchel, A., Silverman, L. B., Schmiegelow, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1636 · Cited by 1,007
Self-citationGuidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885
Metadata
- Authors
- Evans, W. E., Hon, Y. Y., Bomgaars, L., Coutre, S., Holdsworth, M., Janco, R., Kalwinsky, D., Keller, F., Khatib, Z., Margolin, J., Murray, J., Quinn, J., Ravindranath, Y., Ritchey, K., Roberts, W., Rogers, Z. R., Schiff, D., Steuber, C., Tucci, F., Kornegay, N., Krynetski, E. Y., & Relling, M. V.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-04-15
- Volume
- 19
- Issue
- 8
- Pages
- 2293-2301
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2271765448
- Cited by
- 400
- References
- 27
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.